Nanjing Chuangte to Speak at ACCESS CHINA Partnering Forum

Oct 11th, 2023 (Shanghai) — We are glad to announce that Dr. Yongqiang Zhu, the CEO of Nanjing Chuangte, has been invited to present at ACCESS CHINA Partnering Forum on 15:15-15:30, October 17th, China time.

ACCESS CHINA Partnering Forum is the largest corporate access event between Asia and the western biopharma industry.

About Nanjing Chuangte

Nanjing Chuangte Pharmaceutical Technology Co., Ltd. was founded in February 2019. The company is an innovative biotech company specializing in research and development of new drugs. With the enterprise mission of “Health for the public, benefit for the world”, Nanjing Chuangte focus on cancers, cardiovascular and respiratory diseases, and are committed to providing innovative products so as to consistently provide patients with health services, and create value for customers.

The company attaches great importance to R&D innovation and talent introduction, with research and management team of around 40 people. 80% of team members hold the Ph.D./master degrees. The company also employed professors, researchers, senior engineers and many scientific consultants.

The pipeline comprises 19 new drugs in development, with 3 new drugs in clinical trials and all drugs are showing satisfactory data in clinical trials.

About the speaker

Yongqiang Zhu, Ph.D.

CEO of Nanjing Chuangte

Dr. Yongqiang Zhu founded Nanjing Chuangte in February 2019 as the CEO, dedicated to the design and research of new drugs. Dr. Zhu has experience in drug research and development for more than 20 years, and has chaired a number of national and provincial major science and technology projects. In total, 16 clinical approvals were obtained for new drugs (including 3 new drugs of category 1), with one new drug in phase III clinical study, and one new drug been approved for clinical trials both by the FDA and NMPA.

Dr. Zhu received the Bachelor’s degree in Chemistry from Sichuan University, Master’s degree in Organic Chemistry from Huazhong University of Science and Technology, and Ph.D. from Peking University. After that, he joined the Pharmaceutical Research Institute of Simcere as director of the Pharmaceutical Chemistry Laboratory. He then joined Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd. Afterwards he worked as a postdoctoral researcher in the University of Michigan in professor Wang Shaomeng’s team.

Dr Zhu has extensive experience in design of targeted drug and research on drug action at the molecular level, as well as management of a corporate.

About ACCESS CHINA Partnering Forum

ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. We organize a series of online and in-person partnering events since 2019 with the mission to facilitate the collaboration between Western and Eastern biotechs.

This Autumn event, as part of our quarterly series, will feature 40+ leading pharmaceutical companies delivering virtual roadshows to an audience of 500+ participants online. During the event, audience can have access to innovative biopharmas and healthcare products from worldwide.

Event Name: ACCESS CHINA Partnering Forum-2023 Autumn

Date & Time: Oct. 16th-17th, 2023

Location: Zoom Webinar

Content: Keynote Speech, Company Showcase

Participants: Pharma/Biotech senior management and BDs.

View more information at https://biotochina.org/

关于药通中国交易合作论坛2023

“ACCESS CHINA 药通中国交易合作论坛2023”于2023年10月16日至17日线上举办。自2020年始，药通中国论坛系列活动已成功举办14届，成为了海内外生物医药、医疗器械企业寻找合作的领先跨境交易路演平台。这里聚集了海内外医药界顶尖BD和管理人员，为项目交流搭建了高效的沟通渠道，为资产交易创造了宝贵的机会。

大会名称：药通中国交易合作论坛2023

大会日期：2023.10.16-17（线上）

大会内容：主题演讲、海内外优质项目路演

参会观众：海内外医药企业（药企及Biotech）高管及BD、基金高管

查看更多信息： https://biotochina.org/